Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


7th Indo Global Diabetes Summit and Medicare Expo

Bengaluru, India

Aslam Ali Hashmi

MESCO College of Pharmacy, India

Title: Management of type 2 diabetes mellitus: A drug interaction update


Biography: Aslam Ali Hashmi


The incidence of type 2 diabetes has gained its identity as the most prevalent chronic disease worldwide with unavoidable burden to the healthcare system and the society. Despite the advancement in modern medicine practice the clinical effect and outcomes are unenviable which affect health related quality of life. The complication in its management is due to excessive use of medications which has increased enormously in the past time. Furthermore, the existence of co morbidity such as hypertension, CAD, obesity may increase the number of medications which may become appropriate therapy. On the top, the benefits of medications always co-exist with potential suffering, even when the right drug is prescribed and at recommended doses. With this context, the consequence of drug-drug interaction may range from serious to life-threatening clinical condition. Moreover, the inability to differentiate drug-induced manifestation such as hypoglycemia may result in reduction or deletion of dose or increment if hyperglycemia persist, which in turn increases the risk of interactions. The true incidence of drug interactions is unknown as many are not reported, even if reported are not documented as a drug interaction, but rather consider as an adverse drug reaction. Although drug interactions for a few selected drugs are well known, we often ignore the considerable evidence that potential interactions exist in many of the drug therapy prescribed today. In this review we focus on the most frequent drug-drug interactions, in type 2 diabetic patients with co-morbidities, while considering physiological, genetical and environmental factors in diverse patients.